Elotuzumab clinical trials
Also written Empliciti, BMS-901608 and HuLuc63.
How each study uses elotuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elotuzumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Nov 2015 · EMPLICITI · BLA 761035 (FDA, Drugs@FDA)
- European Union
- 11 May 2016 · Empliciti · EMEA/H/C/003967 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
46 studies that test it; most in 2017 (7)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2011 | 5 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 5 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 28
Bristol-Myers Squibb (12) · M.D. Anderson Cancer Center (3) · Dana-Farber Cancer Institute (3) · Mayo Clinic (2) · University of Arkansas (2) · AbbVie (1) · Yale University (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Dexamethasone (15) · Lenalidomide (8) · Pomalidomide (7) · Carfilzomib (4) · Bortezomib (4) · Iberdomide (3) · Daratumumab (2) · Nivolumab (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 5 phase 3 studies under way
Elotuzumab is the comparator. A study of two new drugs counts under both.
- 1Talquetamab · Janssen Research & Development, LLC
- 1Pomalidomide · Janssen Research & Development, LLC
- 1Teclistamab · Janssen Research & Development, LLC
- 1Selinexor · European Myeloma Network B.V.
- 1Cevostamab · Hoffmann-La Roche · next primary completion Nov 2028
- 1Elranatamab · Pfizer
- 1Linvoseltamab · Regeneron Pharmaceuticals · next primary completion Apr 2033
Reaching primary completion within a year · 3
Studies that test elotuzumab.
- Nov 2026A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaEarly Phase 1 · Icahn School of Medicine at Mount Sinai
- Dec 2026A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaPhase 2 · Massachusetts General Hospital
- Apr 2027Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaPhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses elotuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 46
- ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaRecruitingPhase 1Omar Nadeem, MDNCT06518551Written as ElotuzumabHow we know
- Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingPhase 1/2Mayo ClinicNCT06785415Written as ElotuzumabHow we know
- Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02420860Written as ElotuzumabHow we know
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 3AbbVieNCT06158841Written as ElotuzumabHow we know
- Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedPhase 3CelgeneNCT03651128Written as ElotuzumabHow we know
- Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04517851Written as ElotuzumabHow we know
- Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaActive, not recruitingPhase 1/2Yale UniversityNCT05002816Written as ElotuzumabHow we know
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple MyelomaCompletedPhase 1/2SWOG Cancer Research NetworkNCT01668719Written as ElotuzumabHow we know
- Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabCompletedPhase 2Bristol-Myers SquibbNCT02719613Written as ElotuzumabHow we know
- LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaCompletedPhase 2Wake Forest University Health SciencesNCT03361306Written as ElotuzumabHow we know
- Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)TerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04918147Written as elotuzumabHow we know
- A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingPhase 2Massachusetts General HospitalNCT02718833Written as ElotuzumabHow we know
- Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple MyelomaCompletedPhase 2University of ChicagoNCT02969837Written as ElotuzumabHow we know
- Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaActive, not recruitingPhase 2Washington University School of MedicineNCT03030261Written as ElotuzumabHow we know
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaActive, not recruitingEarly Phase 1Icahn School of Medicine at Mount SinaiNCT05560399Written as ElotuzumabHow we know
- Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaCompletedPhase 2Mayo ClinicNCT03713294Written as ElotuzumabHow we know
- Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedPhase 2M.D. Anderson Cancer CenterNCT01729091Written as ElotuzumabHow we know
- Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedPhase 2Dana-Farber Cancer InstituteNCT02375555Written as ElotuzumabHow we know
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance TherapyWithdrawnPhase 2University of ArkansasNCT03000634Written as ElotuzumabHow we know
- Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedPhase 2SCRI Development Innovations, LLCNCT02843074Written as elotuzumabHow we know
See all 46 studies that test elotuzumab →
Given beside what is tested · 10 — elotuzumab is usual care or a partner of the new treatment
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as ElotuzumabHow we know
- Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted TherapiesActive, not recruitingPhase 1Abdullah KhanNCT05981209Written as ElotuzumabHow we know
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaActive, not recruitingPhase 2Medical College of WisconsinNCT04835129Written as ElotuzumabHow we know
- A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Active, not recruitingPhase 1/2CelgeneNCT03989414Written as ElotuzumabHow we know
- FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedPhase 1Fate TherapeuticsNCT04614636Written as ElotuzumabHow we know
- An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedPhase 3Bristol-Myers SquibbNCT02726581Written as ElotuzumabHow we know
- PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TerminatedPhase 3Bristol-Myers SquibbNCT01891643Written as ElotuzumabHow we know
- 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)WithdrawnPhase 2University of ArkansasNCT03003728Written as ElotuzumabHow we know
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedPhase 1PETHEMA FoundationNCT03023527Written as ElotuzumabHow we know
- A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCompletedPhase 1Bristol-Myers SquibbNCT02252263Written as ElotuzumabHow we know
As the comparator · 7 — what is tested is compared with elotuzumab
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as ElotuzumabHow we know
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingPhase 3PfizerNCT06152575Written as ElotuzumabHow we know
- A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple MyelomaRecruitingPhase 3Regeneron PharmaceuticalsNCT05730036Written as ElotuzumabHow we know
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06208150Written as ElotuzumabHow we know
- A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple MyelomaActive, not recruitingPhase 3European Myeloma Network B.V.NCT05028348Written as ElotuzumabHow we know
- Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGITTerminatedPhase 1/2Multiple Myeloma Research ConsortiumNCT04150965Written as Elotuzumab, pomalidomide, dexamethasoneHow we know
- A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)WithdrawnPhase 3CelgeneNCT06232707Written as ElotuzumabHow we know
Codes
What other systems call elotuzumab · ClinicalTrials.gg INT005550
- MeSH (NLM) C546027elotuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1351PE5UGSELOTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1726104Confirmed FDA, Wikidata
- Wikidata Q3723645elotuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66982ElotuzumabOne source FDA
- DrugBank DB06317One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546027 | elotuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1351PE5UGS | ELOTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1726104 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3723645 | elotuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66982 | Elotuzumab | One source FDA |
| DrugBank | DB06317 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.